文献速递基础与转化研究新药、器械与细胞基因治疗研发

代谢干预与T细胞疗法联用增强实体瘤免疫治疗

Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy.
PubMed 文献 · Sci Transl Med · 2020-01-01

该研究将脂质体阿伐麦布通过脂质插入点击到T细胞表面,不干扰T细胞生理功能,在循环和外渗过程中限制在T细胞表面并局部释放,提高T细胞膜胆固醇浓度,诱导T细胞受体快速聚集和持续活化。表面锚定工程化T细胞(包括小鼠TCR转基因CD8+ T细胞或人CAR T细胞)在小鼠黑色素瘤和胶质母细胞瘤模型中表现出优越的抗肿瘤疗效,5只接受表面锚定工程化CAR T细胞治疗的小鼠中3只胶质母细胞瘤完全根除,其他治疗组小鼠生存不超过64天,且未观察到明显全身副作用。

要点

  • 脂质插入法将脂质体阿伐麦布锚定于T细胞表面,不干扰T细胞生理功能。
  • 阿伐麦布在循环和外渗中保留于T细胞表面并局部释放,提高膜胆固醇,诱导TCR聚集和持续活化。
  • 表面锚定工程化T细胞在小鼠黑色素瘤和胶质母细胞瘤模型中显示优越抗肿瘤疗效且无明显全身副作用。

核心结论

  • 表面锚定代谢干预的工程化T细胞可增强实体瘤免疫治疗疗效且安全性良好。

研究设计与样本

  • 临床前研究:将脂质体阿伐麦布通过脂质插入点击到T细胞表面,在小鼠黑色素瘤和胶质母细胞瘤模型中评估疗效。

主要发现

  • 表面锚定工程化T细胞(小鼠TCR转基因CD8+ T细胞或人CAR T细胞)在小鼠黑色素瘤和胶质母细胞瘤模型中表现出优越的抗肿瘤疗效。
  • 5只接受表面锚定工程化CAR T细胞治疗的小鼠中3只胶质母细胞瘤完全根除,其他治疗组小鼠生存不超过64天。
  • 给予工程化T细胞未观察到明显的全身副作用。

临床怎么用

  • 该细胞表面锚定工程化T细胞因制备简单且安全性良好具有转化潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of solid tumors with T cell therapy has yielded limited therapeutic benefits to date. Although T cell therapy in combination with proinflammatory cytokines or immune checkpoints inhibitors has demonstrated preclinical and clinical successes in a subset of solid tumors, unsatisfactory results and severe toxicities necessitate the development of effective and safe combinatorial strategies. Here, the liposomal avasimibe (a metabolism-modulating drug) was clicked onto the T cell surface by lipid insertion without disturbing the physiological functions of the T cell. Avasimibe could be restrained on the T cell surface during circulation and extravasation and locally released to increase the concentration of cholesterol in the T cell membrane, which induced rapid T cell receptor clustering and sustained T cell activation. Treatment with surface anchor-engineered T cells, including mouse T cell receptor transgenic CD8+ T cells or human chimeric antigen receptor T cells, resulted in superior antitumor efficacy in mouse models of melanoma and glioblastoma. Glioblastoma was completely eradicated in three of the five mice receiving surface anchor-engineered chimeric antigen receptor T cells, whereas mice in other treatment groups survived no more than 64 days. Moreover, the administration of engineered T cells showed no obvious systemic side effects. These cell-surface anchor-engineered T cells hold translational potential because of their simple generation and their safety profile.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Hao M, Hou S, Li W, et al. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci Transl Med. 2020. PMID: 33239389. doi:10.1126/scitranslmed.aaz6667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。